Why Amgen Stock Is Down Today Despite Solid Q2 Results
7/8 19:11
By no means were Amgen's (NASDAQ: AMGN) second-quarter numbers "bad." Revenue for most of its core drugs was up year over year, and the slight earnings dip is the predictable result of rising expenses. The pharmaceutical company's outlook remains optimistic as well....